N'oge na-adịbeghị anya, akwụkwọ akụkọ British Journal of Clinical Pharmacology bipụtara ntuziaka ahụike mbụ nke UK Center of Excellence for Regulatory Science and Innovation in Pharmacogenomics (CERSI PGx) mepụtara, nke akpọrọ "Nnwale ụdị mkpụrụ ndụ ihe nketa CYP2C19 maka clopidogrel: Ntuziaka nke UK Center of Excellence mepụtara maka sayensị nchịkwa na ihe ọhụrụ na pharmacogenomics (CERSI PGx)". Akwụkwọ a dị mkpa na-elekwasị anya na uru ahụike nke mkpụrụ ndụ ihe nketa CYP2C19 na nduzi ọgwụgwọ clopidogrel.
Banyere CERSI PGx
CERSI PGx bụ otu n'ime ebe asaa gọọmentị UK kwadoro maka sayensị na ihe ọhụrụ e hiwere na Jenụwarị 2025. Mahadum Liverpool na-edu ya, Innovate UK, Medical Research Council (MRC), Medicines and Healthcare products Regulatory Agency (MHRA), na Office for Life Sciences (OLS) na-akwado ya. Ebe a na-achọ ime ka njikọta pharmacogenomics (PGx) dị ngwa ma dị irè na nke dị irè nke ọrụ ahụike mba (NHS) site n'ịgwọ ihe mgbochi ndị bụ isi. Ntuziaka a bụ ntuziaka ahụike mbụ e nyere kemgbe e guzobere CERSI PGx.
Ihe kpatara CYP2C19 ji dị mkpa maka Clopidogrel
CYP2C19 bụ isi ihe dị mkpa n'ime ezinụlọ enzyme cytochrome P450, bụ ndị na-ahụ maka mmụba metabolism ma ọ bụ ịkwụsị ọrụ nke ọtụtụ ọgwụ. Mgbanwe mkpụrụ ndụ ihe nketa na CYP2C19 na-eduga na nnukwu ọdịiche dị n'etiti onwe onye na metabolism ọgwụ, na-emetụta arụmọrụ na nchekwa.
Clopidogrel bụ ọgwụ mgbochi platelet a na-ejikarị eme ihe maka igbochi ihe ndị na-eme ka thrombosis pụta na ọrịa akwara obi, ọrịa strok ischaemic, ọrịa akwara akụkụ, na fibrillation atrial. Dịka ọgwụ prodrug, clopidogrel chọrọ ka metabolism rụọ ọrụ site na CYP2C19. Ntuziaka a na-ekewa ndị mmadụ n'ime ultrapid, ngwa ngwa, nkịtị, etiti, na nke na-adịghị mma dabere na ụdị mkpụrụ ndụ ihe nketa CYP2C19. Ndị na-ebu mfu nke alleles ọrụ (dịka ọmụmaatụ, CYP2C192 na *3*) - ndị na-ebu metabolizers etiti na nke na-adịghị mma - enweghị ike ime ka clopidogrel rụọ ọrụ nke ọma, na-eduga na mgbochi platelet zuru oke na mmụba nke ohere nke thrombosis ugboro ugboro.
Ugboro ole nke CYP2C192 allele dị ihe dịka 15% na ndị Yuropu, 30% na ndị South Asia, yana 60% na ndị bi na Oceania.
Ndụmọdụ Dị Mkpa: Nnwale CYP2C19 zuru ụwa ọnụ maka Clopidogrel
Ntuziaka ahụ kwuru na, n'agbanyeghị ihe ngosi ahụ, ndị ọrịa niile a na-atụle clopidogrel kwesịrị ịnata ọgwụgwọ.CYP2C19nhazi mkpụrụ ndụ ihe nketa.Dabere na nsonaazụ ya, a ga-eme ka ọgwụgwọ antiplatelet ka mma: +
-Metabolizers na-adịghị mmaEkwesịrị izere clopidogrel ma jiri ọgwụ ndị ọzọ na-adabereghị na metabolism CYP2C19, dịka ticagrelor ma ọ bụ prasugrel.
-Ihe ndị na-eme ka metabolism dị n'etitiEkwesịrị ịtụle ọgwụ ndị ọzọ ma ọ bụ usoro mgbanwe kama ịbawanye dose nke clopidogrel.
Na mba UK, a kwadoro clopidogrel maka mgbochi nke abụọ nke ihe omume atherothrombotic, maka mwakpo ischaemic nke dị n'etiti ruo n'ókè dị elu (TIA) ma ọ bụ strok dị nro, yana maka igbochi ihe omume atherothrombotic na thromboembolic na atrial fibrillation.
Karịa Clopidogrel: Ọgwụ Ndị Ọzọ Ebe Mkpụrụ ndụ ihe nketa CYP2C19 dị oke mkpa
Uru nke CYP2C19 genotyping gbasaara karịa clopidogrel. Dịka nnukwu enzyme na-eme ka ọgwụ gbazere, CYP2C19 na-arụkwa ọrụ dị mkpa na metabolism nke voriconazole, ọtụtụ antidepressants, na proton pump inhibitors (PPIs). Ọtụtụ ntuziaka mba ụwa na nke mba na-akwado ka a na-eduzi genotype maka ọgwụ ndị a.
1. Ọgwụ mgbochi nkụda mmụọ (SSRIs)
Ọgwụ ndị na-egbochi serotonin reuptake (SSRIs) - dịka sertraline, citalopram, na escitalopram - bụ ọgwụ mbụ maka ịda mbà n'obi ma CYP2C19 na-eme ka ha dị iche. Ọrụ enzyme CYP2C19 na-ekpebi kpọmkwem mkpokọta plasma nke ọgwụ ndị a. Ọgwụ ndị na-adịghị mma nwere mbelata 30%–60% na mwepụ ọgwụ, nke na-eme ka ha nwee mmetụta ọjọọ dịka ịgbatị oge QT na ịka nká. Ọgwụ ndị na-ebelata shuga na-enwekarị ike ịmịpụta plasma n'okpuru ọgwụgwọ, na-eduga na nzaghachi ọgwụgwọ na-egbu oge na nnukwu ihe egwu nke ịkwụsị ọgwụ.
Ntuziaka nke 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) na-ekwu na ndị na-anaghị eri ihe na-edozi ahụ na-aṅụ citalopram ma ọ bụ escitalopram nwere nnukwu ihe ize ndụ nke ịgbatị oge QT ma na-atụ aro ka e belata dose ahụ ruo 50%. Ntuziaka nke 2021 Dutch Pharmacogenetics Working Group (DPWG) na-adụ ọdụ na ndị na-eri ihe na-edozi ahụ na-adịghị mma kwesịrị inweta oke dose nke escitalopram belatara site na 50%, nakwa na ndị na-eri ihe na-edozi ahụ na-adịghị edozi ahụ kwesịrị izere escitalopram kpamkpam. Maka sertraline, DPWG na-atụ aro ka a na-aṅụ ọgwụ kwa ụbọchị nke na-agaghị agafe 75 mg na ndị na-eri ihe na-adịghị edozi ahụ na-adịghị mma.
Ihe dị mkpa bụ na e bipụtara n'oge na-adịbeghị anya na Nkwekọrịta Ọkachamara nke China gbasara Nnwale Ọgwụ na Ọrịa Uche (2025) - nke Precision Medicine Collaboration Group nke Chinese Society of Psychiatry mepụtara - gụnyere ndụmọdụ maka genotyping CYP2C19 nke ọma. Nkwupụta nkwekọrịta na-ekwu na a pụrụ ịtụ aro mgbanwe dose site na ntuziaka mba ụwa dịka CPIC na DPWG maka enzymes metabolism ọgwụ (gụnyere CYP2C19) maka ndị China. Ya mere, CYP2C19 genotyping tupu ịmalite ọgwụgwọ SSRI (dịka ọmụmaatụ, escitalopram) na-enye ohere ka e mee ka dose dịkwuo mma ma ọ bụ gbanwee gaa na ọgwụ ndị ọzọ nke CYP2C19 na-anaghị agbanwe agbanwe, si otú a nweta ọgwụgwọ ziri ezi, melite ọnụego nzaghachi, na ibelata ihe omume ndị na-adịghị mma.
2. Ihe mgbochi Proton Pump (PPIs)
A na-ejikarị ihe mgbochi proton pump - gụnyere omeprazole, lansoprazole, na pantoprazole - eme ihe maka nsogbu acid dịka ọrịa gastroesophageal reflux na ọnya afọ. Mmeghachi omume ha dabere na CYP2C19 nke ukwuu. Ndị ọrịa nwere ụdị mkpụrụ ndụ ihe nketa CYP2C19 dị iche iche na-egosi nnukwu mgbanwe na nzaghachi na PPI. Ndị na-ebu ihe ndị na-adịghị arụ ọrụ (*2, *3) amụbaala nke ukwuu na ikpughe ọgwụ, nke nwere ike ime ka mbelata acid dịkwuo elu mana ọ na-emekwa ka ohere nke mmetụta ọjọọ dịkwuo elu. N'ụzọ dị iche, ihe ndị na-eme ka metabolism nkịtị dị obere na plasma ma nwee ike ịnweta mbelata acid na-adịghị ike, ọ bụ ezie na mgbanwe dị n'etiti onwe onye ka dị oke mkpa.
Ntuziaka CPIC nke afọ 2020 maka PPI na-adụ ọdụ ka ndị na-eme ka ọgwụ ndị na-ebelata shuga dị n'ọbara na-aṅụ omeprazole ma ọ bụ ọgwụ ndị yiri ya na-eme ka ọgwụ ahụ gbasaa ngwa ngwa, na-ebute oke mkpokọta plasma na obere mbelata acid. N'ime ndị ọrịa a, a ga-amụba dose ahụ ma nyochaa nzaghachi ọgwụgwọ. Maka ndị na-anaghị eme ka ọgwụ ahụ dị mma, mwepụ ọgwụ na-adị nwayọ ma nwee ike ịbawanye mkpokọta plasma; ọ bụ ezie na arụmọrụ nwere ike ịka mma, a na-amụba ohere nke nsị ọgwụ. Mbelata dose na nlekota nzaghachi bụ ihe ezi uche dị na ya. Ya mere, maka ndị ọrịa na-amalite ọgwụgwọ PPI ma ọ bụ ndị na-enwe mmeghachi omume na-adịghị mma ma ọ bụ mmetụta ọjọọ, a na-atụ aro ka e jiri CYP2C19 genotyping duzie usoro onunu ogwu nkeonwe, mee ka arụmọrụ ka mma, ma belata ihe omume ọjọọ.
3. Voriconazole
Voriconazole bụ ọgwụ nje dị iche iche a na-eji agwọ ọrịa fungal dị oke njọ dịka aspergillosis. O nwere obere usoro ọgwụgwọ: oke oke plasma na-eme ka ohere nke ịta ahụhụ imeju na nsogbu anya dịkwuo elu, ebe obere oke na-eme ka ọgwụgwọ ghara ịdị mma. CYP2C19 na-akpata metabolism nke voriconazole, mgbanwe mkpụrụ ndụ ihe nketa na-emetụtakwa oke plasma ya.
CPIC bipụtara ntuziaka pụrụ iche gbasara CYP2C19 na voriconazole na 2016. O kwuru na ihe ndị na-eme ka ọgwụ dị nro belatara njupụta nke voriconazole ma na-adịghị eru ọkwa ọgwụgwọ achọrọ. Ihe ndị na-eme ka ọgwụ dị nro nwere nnukwu njupụta nke ihe ndị na-adịghị mma na nnukwu ihe egwu nke mmeghachi omume ọjọọ. Ntuziaka CPIC na-enye ndụmọdụ maka usoro ọgwụgwọ dabere na genotype. Dịka ọmụmaatụ, ihe ndị na-eme ka ọgwụ dị nro nke ndị okenye kwesịrị ịnweta ọgwụ ndị ọzọ nke na-adabereghị na metabolism CYP2C19, dị ka isavuconazole, liposomal amphotericin B, ma ọ bụ posaconazole. Ya mere, CYP2C19 genotyping tupu ọgwụgwọ voriconazole na-enye ohere ka a na-enye ọgwụ n'otu n'otu ma belata ihe omume nke ihe ọjọọ metụtara ọgwụ.
Mkpa Ọgwụ: Ime Ka Ọgwụ Dịkwuo Mma
Ntuziaka ọhụrụ ewepụtara ọzọ tinyere CYP2C19 genotyping n'ọkwa kachasị elu n'ọgwụgwọ ziri ezi. Agbanyeghị, ọ dị mkpa ịghọta na ojiji ọgwụgwọ nke CYP2C19 genotyping gafere clopidogrel - site na voriconazole (antifungal) na SSRIs (ọgwụ mgbochi ịda mbà n'obi) ruo na proton pump inhibitors maka mgbochi acid. Genotype CYP2C19 na-arụ ọrụ dị ka "kompas" maka ọgwụgwọ ọgwụ.
Ka ọgwụ nkenke na-enweta nnabata sara mbara, ọtụtụ ntuziaka ndị a ma ama na-etinye mkpụrụ ndụ ihe nketa CYP2C19 n'ime usoro ọgwụgwọ a na-eme kwa ụbọchị. Maka ndị ọrịa, ịmara ụdị mkpụrụ ndụ ihe nketa CYP2C19 nke ha na-enyere ha aka ịghọta profaịlụ nzaghachi ọgwụ nke ha ma na-eme ka mkpebi a na-emekọrịta na dọkịta ha mepụta atụmatụ ọgwụgwọ kwesịrị ekwesị. Maka ndị dọkịta, ijikọta nsonaazụ nnwale mkpụrụ ndụ ihe nketa ebumnuche na mkpebi ọgwụ bụ ụzọ dị ike isi melite mma ọgwụgwọ ma hụ na nchekwa onye ọrịa.
Nnwale Macro na Micro'sNgwọta Mkpụrụ ndụ ihe nketa CYP2C19
Nnwale Macro & Micro na-enye ngwa genotyping CYP2C19 dabere na sistemụ mgbanwe mmụgharị amplification refractory (ARMS) ka mma yana nyocha Taqman nwere njirimara ndị a:
-Mkpuchi allele zuru oke- achọpụtaCYP2C192, *3, na *17na-enweghị ihe dị iche iche dị mkpa.
-Njikwa mma siri ike- gụnyere njikwa na-adịghị mma/nke dị mma, njikwa dị n'ime, na enzyme UDG maka njikwa ogo ọkwa anọ iji hụ na nsonaazụ ziri ezi.
-Mwepụta akpaghị aka- dakọtara na ihe na-ewepụta nucleic acid nke Macro & Micro-Test nke akpaghị aka, na-eme ka arụmọrụ ọrụ dịkwuo mma.
-Ndakọrịta sara mbara- na-arụ ọrụ na ngwa PCR oge a na-ahụkarị n'ahịa, gụnyere ABI 7500 Hongshi SLAN 96P.
-Nkọwa nsonaazụ akpaghị aka– ngwanrọ nyocha raara onwe ya nye (na ABI 7500, SLAN 96P, wdg) na-enye ohere ịkọwa nsonaazụ ozugbo, na-eme ka arụmọrụ dịkwuo mma.
-POCT dị njikere akpaaka– HWTS AIO800 Fully Automatic Nucleic Acid Amplification Analyzer na-enye ohere ka ọrụ "sample in, result out" rụọ ọrụ.
Site na ọganihu na-aga n'ihu nke ọgwụ ọgwụ, a na-atụ anya na genotyping CYP2C19 ga-abara ọtụtụ ndị ọrịa uru, na-ebugharị ọgwụ ziri ezi site na echiche gaa na omume ọgwụgwọ nkịtị. Ntuziaka CERSI PGx ebipụtara ọhụrụ na-eme ka ọrụ dị mkpa nke nnwale CYP2C19 sie ike ọ bụghị naanị maka clopidogrel kamakwa maka ndepụta ọgwụ na-eto eto, gụnyere ọgwụ mgbochi, proton pump inhibitors, na voriconazole. Iji mee ka nnabata nke genotype eduzi ọgwụ dị mfe, ngwọta nnwale a pụrụ ịdabere na ya na nke enyi na enyi dị mkpa. Nchịkọta nnwale pharmacogenomic nke Macro & Micro-Test, nke nwere mkpuchi allele zuru oke, njikwa mma siri ike, na ikpo okwu dị njikere akpaaka, na-achọ ịkwado ndị na-enye nlekọta ahụike na itinye ọgwụ ziri ezi na n'ikpeazụ ichebe ahụike onye ọrịa.
Ngwaahịa ndị metụtara ya:
Ntụaka:
1. Lima JJ, Thomas CD, Barbarino J, na ndị ọzọ. Ntuziaka maka CYP2C19 na Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2020. doi:10.1002/cpt.20151.
2.Lee CR, Luzum JA, Sangkuhl K, na ndị ọzọ. Ntuziaka Mmekọrịta Mmezu Ọgwụ Clinical Pharmacogenetics maka Ọgwụgwọ CYP2C19 Genotype na Clopidogrel: Mmelite 2022. Clin Pharmacol Ther. 2022. doi:10.1002/cpt.25261.
3. National Institute for Health and Care Excellence (NICE). Nnwale ụdị mkpụrụ ndụ ihe nketa CYP2C19 iji duzie ojiji clopidogrel mgbe ọrịa strok ischaemic ma ọ bụ mwakpo ischaemic nwa oge gasịrị. Ntuziaka nchọpụta DG59. Ebipụtara: 31 Julaị 2024.
4. Òtù Mmekọrịta Nnyocha Ọgwụ Precision nke Òtù Ndị Ọrịa Uche nke China. Nkwekọrịta ndị ọkachamara na nnwale ọgwụ na psychiatry (2025) [Zhonghua Jing Shen Ke Za Zhi].Akwụkwọ akụkọ China nke Ọrịa Uche. 2025;58(6):434-445. doi:10.3760/cma.j.cn11366120240611-00181
5.Dello Russo C, Frater I, Kuruvilla R, na ndị ọzọ. Nnwale ụdị mkpụrụ ndụ ihe nketa CYP2C19 maka clopidogrel: Ntuziaka nke UK Center of Excellence mepụtara maka sayensị nchịkwa na ihe ọhụrụ na pharmacogenomics (CERSI-PGx). Br J Clin Pharmacol. 2025. DOI: 10.1093/bjcp/…
6.Moriyama B, Owusu Obeng A, Barbarino J, na ndị ọzọ. Ntuziaka maka CYP2C19 na Voriconazole Therapy (CPIC). Clin Pharmacol Ther. 2017;102(1):45-51. doi:10.1002/cpt.595.
7. Bousman CA, Stevenson JM, Ramsey LB, na ndị ọzọ. Ntuziaka maka CYP2D6, CYP2C19, CYP2B6, SLC6A4, na HTR2A Genotypes na Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68. doi:10.1002/cpt.2903.
8.Brouwer JMJL, Nijenhuis M, Soree B, na ndị ọzọ. Ntuziaka Dutch Pharmacogenetics Working Group (DPWG) maka mmekọrịta mkpụrụ ndụ ihe nketa na ọgwụ dị n'etiti CYP2C19 na CYP2D6 na SSRIs. Eur J Hum Genet. 2021. doi:10.1038/s41431-021-00894-2.
Oge ozi: Eprel-22-2026